Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Roche Forges Ahead With Taspoglutide Despite Cancer Signal With Competitor GLP-1

This article was originally published in The Pink Sheet Daily

Executive Summary

Roche expects Phase III data on the type 2 diabetes drug to be available by the end of the year and maintains that any carcinogenicity issue is rodent-specific.
Advertisement

Related Content

Victoza Clears European Regulators Without Thyroid Cancer Restrictions
Victoza Clears European Regulators Without Thyroid Cancer Restrictions
Lilly Provides Regulatory Update On Two Key Drugs: Zyprexa LAI, Byetta LAR
Lilly Provides Regulatory Update On Two Key Drugs: Zyprexa LAI, Byetta LAR
No Victory For Victoza: FDA Panel Splits On Whether Cancer Signal Should Block Approval
No Victory For Victoza: FDA Panel Splits On Whether Cancer Signal Should Block Approval
FDA’s Diabetes Guidance On CV Risk Will Get First Test With Pending NDAs

Topics

Advertisement
UsernamePublicRestriction

Register

PS069288

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel